Innovative Clinical Trial Design via Artificial Intelligence Identifies Effective Drug and Its Most Efficacious Dose for Treating Early Alzheimer Disease

Phase 3 clinical trials are the most expensive part of drug development, and the most important hurdle to regulatory approval. More than 95% of phase 3 trials in Alzheimer’s disease fail. The main reason is a poor foundation, namely, inadequate or misleading phase 2 trials. Dr. Donald Berry, Founder of Berry Consultants and Founder and Professor of the Department of Biostatistics at the University of Texas MD Anderson Cancer Center, along with his son Dr. Scott Berry, President of Berry Consultants, are committed to turning the tide. Their revolutionary methodology involves adaptive clinical trial design within a Bayesian statistical approach.